A phase II, dose ranging, multi-centre study to evaluate the safety and efficacy of combretastatin A4 phosphate for treating subfoveal choroidal neovascularization in subjects with pathologic myopia Not provided at time of registration

• Country Canada, Russian Federation, Taiwan, Province of China, United States
• organs None
• Specialty None